Please enable JS

ARTICLES & TESTIMONIALS

GHLF supports KY SB 134

Mar 15/50SN Staff/ Letters and Testimony

SB 134 takes positive steps toward updating Kentucky law to cover biologics and biosimilars in
a way that protects patients. As you know, unlike traditional chemical drugs, biologics are
unique, complex structures made from living cells that are not easily replicated. A small change
or difference in the biosimilar or biologic manufacturing process has the potential to adversely
impact the patient.

READ MORE

GHLF supports CT SB 313

Mar 07/50SN Staff/ Letters and Testimony

SB 313 takes positive steps toward updating Connecticut law to cover biologics and biosimilars
in a way that protects patients.

READ MORE

Victory in the USA

Mar 01/50SN Staff/ Victories

The committee will discuss biologics license application (BLA) 125544, for CT-P13, a
proposed biosimilar to Janssen Biotech Inc.’s REMICADE (infliximab), submitted by Celltrion,
Inc.

READ MORE

Welcoming Commissioner Califf

Mar 01/50SN Staff/ Letters and Testimony

Dr. Califf:

Congratulations on your confirmation by the U.S. Senate to serve as the 22nd Commissioner of the U.S. Food and Drug Administration . You join a distinguished list of public health leaders who have headed one of the federal government’s most important agencies.

READ MORE

GHLF letter supporting ID HB 483

Feb 22/50SN Staff/ Letters and Testimony

Chairman Wood,

The Global Healthy Living Foundation (GHLF) is a 501 (c)(3) patient group that works to
improve the quality of life for people with chronic disease, often focusing on those least able to advocate for themselves.

READ MORE